Triveni Bio is a clinical-stage biotechnology company in Watertown, Massachusetts building first-in-class antibody therapeutics for immunological and inflammatory (I&I) diseases. Born from the 2023 merger of Amagma Therapeutics and Modify Therapeutics, the company pairs a genetics-informed approach with advanced antibody engineering to target root-cause biology rather than just downstream inflammation. Its lead program, TRIV-509, is a half-life-extended monoclonal antibody that inhibits active kallikreins 5 and 7 (KLK5/7) and is in a global Phase 2 proof-of-concept study for moderate-to-severe atopic dermatitis. Backed by roughly $223M across Series A and Series B rounds, Triveni aims to repair the skin barrier and break what it calls efficacy ceilings in dermatology and beyond.
Crossbow Therapeutics is a Cambridge, Massachusetts biotechnology company building a new class of cancer immunotherapies. Its T-Bolt platform engineers TCR-mimetic antibodies - T-cell engagers that recognize tiny peptide fragments displayed on a cancer cell's surface (peptide-HLA complexes), opening up intracellular proteins that conventional antibodies cannot reach. The lead program, CBX-250, is a first-in-class T-cell engager in a Phase 1 trial for relapsed or refractory myeloid malignancies. Backed by more than $157M in venture funding, Crossbow aims to expand the universe of targetable cancer antigens.
Abdera Therapeutics is a precision oncology biotech engineering antibody-based radiopharmaceuticals that deliver therapeutic radioisotopes directly to tumor cells while sparing healthy tissue. Built around its proprietary ROVEr platform, the company is advancing ABD-147 in Phase 1 trials for small cell lung cancer and large cell neuroendocrine carcinoma, with a second program, ABD-320, on deck.
Roy Maute is co-founder and CEO of Pheast Therapeutics, a clinical-stage biotech in Redwood City, CA, developing macrophage-targeted cancer immunotherapies. Trained at UC Berkeley, Columbia (PhD, Genetics), and Stanford (postdoc under Irving Weissman), Maute has built a career at the intersection of innate immunology and drug development. Before Pheast, he co-founded Ab Initio Biotherapeutics (acquired by Ligand in 2019) and led translational research at Forty Seven Inc. ahead of its $4.9B acquisition by Gilead in 2020. At Pheast, he is advancing PHST001, a novel anti-CD24 antibody that teaches macrophages to eat cancer cells, currently in Phase 1 clinical trials with FDA Fast Track Designation for ovarian cancer.